In vitro and in vivo antifungal activities of the marine sponge constituent spongistatin

Medical Mycology

Volumn 43, Issue 5, 2005, Pages 453-463

  Pettit, Robin K ^a   Woyke, Tanja ^a   Pon, Sandy ^a   Cichacz, Zbigniew A ^a   Pettit, George R ^a   Herald, Cherry L ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Candida albicans; Cryptococcus neoformans; Hyrtios erecta; Microtubule; Postantifungal effect

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; SPONGISTATIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; BODY BURDEN; CANDIDIASIS; CELL BUDDING; CELL METABOLISM; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CRYPTOCOCCOSIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; FLUORESCENCE MICROSCOPY; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; KIDNEY INFECTION; LUNG INFECTION; MICROTUBULE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SERUM; SPONGE (PORIFERA);

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; MACROLIDES; MICE; MICROBIAL SENSITIVITY TESTS; MICROTUBULES; MODELS, ANIMAL; PORIFERA;

CANDIDA ALBICANS; FILOBASIDIELLA NEOFORMANS; HYRTIOS ERECTA; MURINAE;

EID: 24644465514     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780500050598     Document Type: Article

References (48)

1. Cardenas ME, Cruz MC, Del Poeta M, et al. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev 1999; 12: 583-611.
2. Pettit GR, Cichacz ZA, Gao F, et al. Isolation and structure of the remarkable human cancer cell growth inhibitors spongistatins 2 and 3 from an Eastern Indian Ocean Spongia spp. J Chem Soc Chem Commun 1993; 14: 1166-1168.
3. Pettit GR, Cichacz ZA, Herald CL, et al. Isolation and structure of spongistatin 1. J Org Chem 1993; 58: 1302-1304.
4. Pettit GR, Herald CL, Cichacz ZA, et al. Antineoplastic agents 293. The exceptional human cancer cell growth inhibitors spongistatins 6 and 7. N Prod Lett 1993; 3: 239-244.
5. Pettit GR, Herald CL, Cichacz ZA, et al. Isolation and structure of the powerful human cancer cell growth inhibitors spongistatins 4 and 5 from an African Spirastrella spinispirulifera (Porifera). J Chem Soc Chem Commun 1993; 24: 1805-1807.
6. Paterson I, Chen DYK, Coster MJ, et al. Stereocontrolled total synthesis of (+)-altohytrin A/spongistatin 1. Angew Chem (Int Edn) 2001; 40: 4055-4060.
7. Smith AB, Doughty VA, Lin QY, et al. The spongistatins: Architecturally complex natural products. Part one: a formal synthesis of (+)-spongistatin 1 by construction of an advanced ABCD fragment. Angew Chem (Int Edn) 2001; 40: 191-195.
8. Pettit RK, McAllister SC, Pettit GR, et al. A broad spectrum antifungal from the marine sponge Hyrtios. Int J Antimicrob Agents 1998; 9: 147-152.
9. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard. Document M27-A2, 2002.
10. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard. Document M38-A, 2002.
11. Sanglard D, Ischer D, Bille J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother 2001; 45: 1174-1183.
12. Manavathu EK, Vazquez JA, Chandrasekar PH. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent. Int J Antimicrob Agents 1999; 12: 213-219.
13. Cross EW, Park S, Perlin DS. Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb Drug Resist 2000; 6: 155-161.
14. Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V (ed.). Antibiotics in Laboratory Medicine, 3rd edn. Baltimore: Williams & Wilkins, 1991: 403-31.
15. Brummer E, Maqbool A, Stevens DA. In vivo GM-CSF prevents dexamethasone suppression of killing of Aspergillus fumigatus conidia by bronchoalveolar macrophages. J Leuk Biol 2001; 70: 868-872.
16. Hata K, Kimura J, Miki H, et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of Aspergillosis, Candidiasis, and Cryptococcosis. Antimicrob Agents Chemother 1996; 40: 2243-2247.
17. Pringle JR, Adams AE, Drubin DG, et al. Immunofluoresence methods for yeasts. Methods Enzymol 1991; 194: 565-602.
18. Woyke T, Roberson RW, Pettit GR, et al. Effect of auristatin PHE on microtubule integrity and nuclear localization in Cryptococcus neoformans. Antimicrob Agents Chemother 2002; 46: 3802-3808.
19. MacKenzie DW, Odds FC. Non-identity and authentication of two major reference strains of Candida albicans. J Med Vet Mycol 1991; 29: 255-261.
20. Jessup CJ, Wallace TL, Ghannoum MA. Evaluation of antifungal activity of nyotran against various pathogenic fungi. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Washington, DC: American Society for Microbiology, 1997: 37.
21. Huffaker TC, Thomas JH, Botstein D. Diverse effects of betatubulin mutations on microtubule formation and function. J Cell Biol 1988; 106: 1997-2010.
22. Jacobs CW, Adams AE, Szaniszlo PJ, et al. Functions of microtubules in the Saccharomyces cerevisiae cell cycle. J Cell Biol 1988; 107: 1409-1426.
23. Pringle JR, Hartwell LH. Saccharomyces cerevisiae cell cycle. In: Strathern JN, Jones EW, Broach JR (eds). Molecular Biology of the Yeast Saccharomyces. Harbor, NY: Cold Spring Harbor, 1981: 97-142.
24. Del Poeta M, Chen S, Von Hoff D, et al. Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother 1999; 43: 2862-2868.
25. Ghannoum MA, Motawy MS, Abu-Hatab MA, et al. Interactive effect of antifungal and antineoplastic agents on yeasts commonly prevalent in cancer patients. Antimicrob Agents Chemother 1989; 33: 726-730.
26. Holloman DW, Butters JA, Barker H. Tubulins: a target for antifungal agents. In: Bentley PH, O'Hanlon PJ (eds). Anti-infectives: Recent Advances in Chemistry and Structure Activity Relationships. London: Royal Society of Chemistry, 1997: 152-156.
27. Little M, Seehaus T. Comparative analysis of tubulin sequences. Comp Biochem Physiol B 1988; 90: 655-670.
28. Woyke T, Pettit GR, Winkelmann G, et al. In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE. Antimicrob Agents Chemother 2001; 45: 967-1000.
29. Bai R, Cichacz ZA, Herald CL, et al. Spongistatin 1, a highly cytotoxic, sponge-derived marine natural product that inhibits mitosis, a microtubule assembly, and the binding of vinblastine to tubulin. Mol Pharmacol 1993; 44: 757-766.
30. Ovechkina YY, Pettit RK, Cichacz ZA, et al. Unusual antimicrotubule activity of the antifungal agent spongistatin 1. Antimicrob Agents Chemother 1999; 43: 1993-1999.
31. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V (ed.). Antibiotics in Laboratory Medicine, 3rd edn. Baltimore: Williams & Wilkins, 1996: 296-329.
32. Turnidge JD, Gudmundsson S, Vogelman B, et al. The post-antibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 1994; 34: 83-92.
33. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial bloodstream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagnos Microbiol Inf Dis 1998; 30: 121-129.
34. Beck-Saguě CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-1251.
35. Birley HD, McDonald P, Parry C, et al. Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int J STD AIDS 1995; 6: 353-355.
36. Joseph-Horne THD. Molecular mechanisms of azole resistance in fungi. FEMS Microbiol Lett 1997; 149: 141-149.
37. Joseph-Horne THD, Loeffler RS, Kelly SL. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother 1995; 39: 1526-1529.
38. Viard JP, Pertuiset N, Rothschild C, et al. Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole. Lancet 1995; 346: 118.
39. Agard DA, Hiraoka Y, Shaw P, et al. Fluorescence microscopy in three dimensions. Methods Cell Biol 1989; 30: 353-377.
40. Scalettar BA, Swedlow JR, Sedat JW, et al. Dispersion, aberration and deconvolution in multi-wavelength fluorescence images. J Microsc 1996; 182: 50-60.
41. Amberg DC. Three-dimensional imaging of the yeast actin cytoskeleton through the budding cell cycle. Mol Biol Cell 1998; 9: 3259-3262.
42. McNally JG, Karpova T, Cooper J, et al. Three-dimensional imaging by deconvolution microscopy. Methods 1999; 19: 373-385.
43. King SM, Hyams JS. The mitotic spindle of Sacchromyces cerevisiae: assembly, structure and function. Micron 1982; 13: 93-117.
44. Heath IB, Ashton ML, Kaminskyj SGW. Mitosis as a phylogenetic marker among the yeasts- review and observations on novel mitotic systems in freeze-substituted cells of the Taphrinales. Stud Mycol 1987; 30: 1696-1725.
45. McCully EK, Robinow CF. Mitosis in heterobasidiomycetous yeasts. I. Leucosporidium scotti (Candida scotti). J Cell Sci 1972; 10: 857-881.
46. Mochizuki T. Three-dimensional reconstruction of mitotic cells of Cryptococcus neoformans based on serial selection electron microscopy. Nippon Ishinkin Gakkai Zasshi 1998; 39: 123-127.
47. Mochizuki T, Tanaka S, Watanabe S. Ultrastructure of the mitotic apparatus in Cryptococcus neoformans. J Med Vet Mycol 1987; 25: 223-233.
48. Taylor JW, Wells K. A light and electron microscopic study of mitosis in Bullera alba and the histochemistry of some cytoplasmic substances. Protoplasma 1979; 98: 31-62.